Michał Jakubczyk

Michał Jakubczyk

Auto-generated profile, based on publicly available information

Michał Jakubczyk

SGH Warsaw School of Economics, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2017 in Central European Journal of Operations Research
Verified
Journal Article
Open access
PDF file
BKBogumił Kamiński
Bogumił Kamiński
MJMichał Jakubczyk
Michał Jakubczyk
PSPrzemyslaw Szufel
Przemyslaw Szufel
In the paper, we consider sequential decision problems with uncertainty, represented as decision trees. Sensitivity analysis is always a crucial element of decision making and in decision trees it often focuses on probabilities. In the stochastic model considered, the user often has only limited information about the true values of probabilities. We develop a framework for performing sensitivity analysis of optimal strategies accounting for this distributional uncertainty. We design this robust optimization approach in an intuitive and not overly technical way, to make it simple to apply in daily managerial practice. The proposed framework allows for (1) analysis of the stability of the expected-value-maximizing strategy and (2) identification of strategies which are robust with respect to pessimistic/optimistic/mode-favoring perturbations of probabilities. We verify the properties of our approach in two cases: (a) probabilities in a tree are the primitives of the model and can be modified independently; (b) probabilities in a tree reflect some underlying, structural probabilities, and are interrelated. We provide a free software tool implementing the methods described.

1 February 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
Maksymilian OpolskiMaksymilian Opolski
Maksymilian Opolski
SAStephan Achenbach
Stephan Achenbach
ASAnnika Schuhbäck
Annika Schuhbäck
ARAndreas Rolf
Andreas Rolf
HMHelge Möllmann
Helge Möllmann
CHChristian W. Hamm
Christian W. Hamm

3 June 2019 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
DGDominik Golicki
Dominik Golicki
MJMichał Jakubczyk
Michał Jakubczyk
KGKatarzyna Graczyk
Katarzyna Graczyk
MNMaciej Niewada
Maciej Niewada
Cost-utility analyses are becoming increasingly important in Central and Eastern Europe. We aimed to develop a Polish utility tariff for EQ-5D-5L health states.

1 March 2010 in Value in Health
Verified
Journal Article
Closed access
DGDominik Golicki
Dominik Golicki
MJMichał Jakubczyk
Michał Jakubczyk
MNMaciej Niewada
Maciej Niewada
WWWitold Wrona
Witold Wrona
JBJan J.V. Busschbach
Jan J.V. Busschbach

26 July 2020 in Surgery
Verified
Journal Article
Open access
PDF file
MZMichał Zawistowski
Michał Zawistowski
JNJoanna Nowaczyk
Joanna Nowaczyk
MJMichał Jakubczyk
Michał Jakubczyk
PDPiotr Domagała
Piotr Domagała
Background Many patients with hepatic tumors cannot benefit from resection owing to the difficult anatomic sites of their lesions. Some of these patients might be eligible for ex vivo liver resection and autotransplantation. This procedure consists of complete hepatectomy, extracorporeal liver resection, and autotransplantation of the remnant liver. Methods Four databases were searched for studies reporting cases of ex vivo liver resection and autotransplantation. Outcomes of this procedure were evaluated by meta-analysis of proportions with random effects model and individual participant data analysis. Results Fifty-three studies were assessed. Meta-analysis revealed an R0 resection rate of 93.4% (95% confidence interval: 81.0–97.9%, I2 = 0%), a frequency of major surgical complications of 24.5% (95% confidence interval, 16.9–34.3%, I2 = 26%), a 30-day mortality of 9.5% (95% confidence interval: 5.9–14.9%, I2 = 0%), and a 1-year survival of 78.4% (95% confidence interval: 62.2–88.8%, I2 = 64%). We were able to obtain the individual participant data in 244 patients; R0 resection was achieved in 98.6%, with no obvious difference between analyzed subgroups. The 30-day mortality and 1-year survivals were 7.9% and 82.1%, respectively. For groups with malignant and nonmalignant tumors, the 30-day mortalities were 11.3% vs. 6.3% (P = .181), and 1-year survivals were 65.0% vs. 89.7% (P < .001). When comparing those with malignant versus those with nonmalignant lesions, major surgical complications occurred in 50.0% vs. 21.0%; P < .001). Regression analysis revealed that outcomes of patients with benign tumors were better compared with those with malignant tumors (1-year survival, odds ratio: 4.629; 95% confidence interval: 2.181–10.097, P < .001). Conclusion Ex vivo liver resection and autotransplantation facilitates radical treatment in selected patients with conventionally unresectable hepatic tumors and normal liver function. The outcomes of treatment of malignant lesions appear to be less satisfactory.

1 September 2014 in Value in Health Regional Issues
Verified
Journal Article
Closed access
JJJoanna Jakubiak-Lasocka
Joanna Jakubiak-Lasocka
MJMichał Jakubczyk
Michał Jakubczyk